Inge Verbrugge

St Andrews Place
East Melbourne, VIC 3002, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal: Journal for immunotherapy of cancer

Published: June 10, 2026

Pharmacodynamic, prognostic, and predictive biomarkers in severe and critical COVID-19 patients treated with sirukumab.

Pharmacodynamic, prognostic, and predictive biomarkers in severe and critical COVID-19 patients treated with sirukumab.

Journal: Scientific reports

Published: May 10, 2024

The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19.

The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19.

Journal: The Journal of infection

Published: February 20, 2024

A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults.

A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults.

Journal: Antiviral therapy

Published: May 18, 2023

PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice.

PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice.

Journal: The Journal of clinical investigation

Published: April 03, 2023

Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants.

Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants.

Journal: Antiviral therapy

Published: January 24, 2023

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells.

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells.

Journal: Cell reports

Published: April 23, 2020

Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system.

Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system.

Journal: Clinical and translational radiation oncology

Published: April 15, 2020

Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity.

Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity.

Journal: Cancer immunology research

Published: September 18, 2018

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.

Journal: International journal of molecular sciences

Published: October 28, 2016

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.

Journal: Frontiers in oncology

Published: August 20, 2016

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

Journal: Oncoimmunology

Published: August 16, 2016

Showing 1-12 of 22

Last Updated: 09/26/2026